home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Unexpected Tumour Growth?

  April, 3 2009 2:53
your information resource in human molecular genetics

Blood vessel inhibitors have been pursued as anticancer agents, but in low doses they may actually promote blood-vessel formation and tumour growth in mice. The results, published online in Nature Medicine, call for a reassessment of these inhibitors as anticancer agents, with implications for their potential use in humans.

Certain inhibitors of integrins -- cell surface receptors that define cellular shape, mobility, and regulate the cell cycle -- have entered clinical trials as agents for cancer treatment, owing to their ability to prevent angiogenesis (blood-vessel growth), but their success has been limited. Andrew Reynolds, Kairbaan Hodivala-Dilke and their colleagues show that low concentrations of integrin inhibitors can paradoxically stimulate tumour growth and tumour angiogenesis by altering the trafficking of one specific integrin and of a well known proangiogenic molecule.

Author contact:

Andrew Reynolds (Institute of Cancer Research, London, UK)
E-mail: andrew.reynolds@icr.ac.uk

Kairbaan Hodivala-Dilke (Cancer Research UK, London, UK)
E-mail: andrew.reynolds@icr.ac.uk

Abstract available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.